trending Market Intelligence /marketintelligence/en/news-insights/trending/udeb0HJl5cfYZdsw50Xd3g2 content esgSubNav
In This List

Zogenix reverts rights to psychosis drug back to DURECT

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy

Blog

Commercial Banking Newsletter June Edition - 2022


Zogenix reverts rights to psychosis drug back to DURECT

DURECT Corp. and Zogenix Inc. terminated a 2011 agreement to develop and commercialize a psychosis treatment.

Zogenix completed several phase 1 clinical trials for the investigational drug Relday and reported that it was generally safe and well-tolerated.

The company returned development and commercialization rights to Durect and will also transfer all regulatory filings and development information.